Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology plc (NASDAQ: MURA) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $18.00 price target on the stock.
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Highlights Clinical Trials During It's Maiden Investor Day [Forbes]